Hans-Joachim Anders Selected Research

BX 471

4/2005	Delayed chemokine receptor 1 blockade prolongs survival in collagen 4A3-deficient mice with Alport disease.
12/2004	CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome.
6/2004	Late onset of treatment with a chemokine receptor CCR1 antagonist prevents progression of lupus nephritis in MRL-Fas(lpr) mice.
2/2004	Chemokine receptor CCR1 but not CCR5 mediates leukocyte recruitment and subsequent renal fibrosis after unilateral ureteral obstruction.
1/2002	A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hans-Joachim Anders Research Topics

Disease

73	Inflammation (Inflammations) 11/2022 - 02/2003
50	Lupus Nephritis 01/2021 - 03/2004
34	Glomerulonephritis 09/2020 - 05/2001
30	Kidney Diseases (Kidney Disease) 01/2022 - 01/2004
30	Necrosis 01/2021 - 09/2009
26	Fibrosis (Cirrhosis) 02/2020 - 06/2001
23	Chronic Renal Insufficiency 01/2022 - 02/2003
23	Proteinuria 01/2022 - 05/2001
23	Systemic Lupus Erythematosus (Libman-Sacks Disease) 03/2021 - 03/2004
15	Diabetic Nephropathies (Diabetic Nephropathy) 12/2022 - 04/2007
15	Acute Kidney Injury (Acute Renal Failure) 01/2022 - 09/2009
14	Infections 01/2022 - 02/2003
11	Renal Insufficiency (Renal Failure) 12/2021 - 06/2004
11	Atrophy 01/2020 - 12/2004
10	Neoplasms (Cancer) 01/2022 - 06/2012
10	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 01/2006
9	Type 2 Diabetes Mellitus (MODY) 01/2022 - 03/2008
8	Nephrocalcinosis 01/2021 - 01/2013
8	Albuminuria 01/2019 - 05/2001
7	Reperfusion Injury 01/2021 - 01/2012
7	Nephritis 12/2020 - 04/2008
6	Ischemia 02/2020 - 02/2003
6	Virus Diseases (Viral Diseases) 05/2014 - 01/2006
5	COVID-19 01/2022 - 01/2020
5	Vasculitis (Vasculitides) 10/2021 - 05/2014
5	Kidney Calculi (Kidney Stone) 01/2021 - 03/2017
5	Wounds and Injuries (Trauma) 01/2020 - 08/2013
5	Chronic Kidney Failure (Chronic Renal Failure) 01/2020 - 05/2004
4	Hyperoxaluria (Oxaluria) 01/2021 - 03/2017
4	Atherosclerosis 10/2020 - 06/2011
4	Thrombosis (Thrombus) 01/2020 - 02/2009
4	Body Weight (Weight, Body) 01/2019 - 06/2002
4	Hereditary Nephritis (Alport Syndrome) 01/2017 - 03/2009
4	Disease Progression 11/2015 - 11/2005
4	Immune Complex Diseases (Immune Complex Disease) 11/2011 - 08/2007
3	IGA Glomerulonephritis (IGA Nephropathy) 01/2022 - 04/2010
3	Thrombotic Microangiopathies 12/2021 - 10/2015
3	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis 12/2021 - 01/2020
3	Hypertrophy 01/2018 - 03/2010

Drug/Important Bio-Agent (IBA)

26	CytokinesIBA 08/2022 - 02/2003
26	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2022 - 03/2004
26	Antigen-Antibody Complex (Immune Complex)IBA 01/2020 - 05/2001
23	ChemokinesIBA 12/2017 - 05/2001
21	AutoantibodiesIBA 10/2021 - 06/2004
21	Messenger RNA (mRNA)IBA 01/2021 - 01/2002
19	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 02/2003
15	InflammasomesIBA 01/2019 - 01/2011
15	Chemokine ReceptorsIBA 07/2011 - 05/2001
13	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2002
12	OxalatesIBA 01/2021 - 03/2014
11	Immunoglobulin G (IgG)IBA 01/2019 - 12/2006
10	Pharmaceutical PreparationsIBA 01/2022 - 01/2002
10	Histones (Histone)IBA 01/2019 - 03/2010
9	Antiviral Agents (Antivirals)IBA 01/2020 - 09/2009
8	RNA (Ribonucleic Acid)IBA 01/2020 - 05/2005
7	Uric Acid (Urate)IBA 11/2022 - 03/2014
7	LigandsIBA 01/2022 - 06/2003
7	AutoantigensIBA 10/2019 - 12/2009
7	CreatinineIBA 11/2016 - 06/2002
7	Nucleic AcidsIBA 09/2009 - 01/2006
6	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 04/2017
6	SodiumIBA 01/2022 - 04/2017
6	Calcium OxalateIBA 01/2021 - 01/2013
6	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2021 - 02/2009
6	Interleukin-6 (Interleukin 6)IBA 02/2020 - 08/2007
6	CollagenIBA 04/2017 - 01/2002
5	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2022 - 04/2017
5	VaccinesIBA 01/2022 - 03/2021
5	SteroidsIBA 12/2021 - 09/2011
5	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 12/2021 - 12/2018
5	Complement System Proteins (Complement)IBA 01/2020 - 04/2008
5	nutlin 3IBA 01/2016 - 11/2011
5	Pattern Recognition ReceptorsIBA 01/2016 - 08/2013
5	BX 471IBA 04/2005 - 01/2002
4	ElementsIBA 01/2022 - 02/2015
4	Interferon Type IIBA 03/2021 - 05/2005
4	Biomarkers (Surrogate Marker)IBA 01/2021 - 02/2009
4	Etanercept (Enbrel)FDA Link 01/2021 - 08/2010
4	Biological ProductsIBA 01/2019 - 01/2014
4	Doxorubicin (Adriamycin)FDA LinkGeneric 12/2018 - 12/2004
4	Immunosuppressive Agents (Immunosuppressants)IBA 12/2017 - 04/2012
4	Interleukin-18 (Interleukin 18)IBA 12/2015 - 01/2011
4	InterferonsIBA 09/2015 - 11/2009
4	InterleukinsIBA 05/2015 - 09/2009
4	Chemokine CCL5IBA 06/2003 - 05/2001
3	Sodium-Glucose Transporter 2 InhibitorsIBA 12/2022 - 01/2019
3	MicroRNAs (MicroRNA)IBA 01/2022 - 01/2021
3	COVID-19 VaccinesIBA 01/2022 - 01/2021
3	Toll-Like Receptor 2IBA 01/2022 - 09/2009
3	AntibodiesIBA 12/2021 - 04/2008
3	Peptide Hydrolases (Proteases)FDA Link 10/2021 - 01/2012
3	Protein Kinases (Protein Kinase)IBA 01/2021 - 11/2014
3	Mycophenolic Acid (Cellcept)FDA LinkGeneric 01/2021 - 09/2011
3	Phosphotransferases (Kinase)IBA 10/2020 - 12/2016
3	Type I Tumor Necrosis Factor ReceptorsIBA 01/2020 - 12/2016
3	Interleukin-22 (IL-22)IBA 01/2018 - 05/2014
3	Chemokine CXCL12IBA 12/2017 - 07/2011
3	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 12/2017 - 07/2011
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2017 - 08/2010

Therapy/Procedure

28	Therapeutics 01/2022 - 12/2006